Comparison of the effects of semaglutide on liver histology in patients with non-alcoholics steatohepatitis cirrhosis between machine learning model assessment and pathologist evaluation

In trials of non-alcoholic steatohepatitis (NASH), liver biopsies are evaluated by pathologists; however, machine learning (ML) has shown promise in assessing biopsies. PathAI has developed ML models to provide such assessments. This post-hoc analysis included data from a randomized, double-blind, placebo-controlled phase 2 trial (NCT03987451) of patients with compensated NASH cirrhosis to study the effects of semaglutide on individual histological components of NASH assessed by the ML models.